LeafNLP Demos
Back to explore

Report #2885090

Received Feb 10, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
87 yrs
State
TX
Recovered
Unknown
Vaccinated
Dec 15, 2025
Onset
Dec 15, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2X5FN4—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

wants the patient to receive a third dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a elderly female patient who received Herpes zoster (Shingrix) (batch number X5FN4, expiry date 17-JUN-2027) for prophylaxis. Previously administered products included Shingrix (received first dose on 14-NOV-2020 with batch number 3R774 and having expiry date 03-AUG-2022). On 15-DEC-2025, the patient received the 2nd dose of Shingrix. On 15-DEC-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: wants the patient to receive a third dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 05-FEB-2026 The patient reported that the prescribing physician had wanted them to receive a third dose. The batch number was provided and a request for this information has been made.